Compounds > imatinib mesylate
Page last updated: 2024-09-03

imatinib mesylate and Leukemia, Lymphocytic

imatinib mesylate has been researched along with Leukemia, Lymphocytic in 10 studies

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's9 (90.00)29.6817
2010's1 (10.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chan, GC; Fung, KL; Liang, RH1
Gesbert, F; Griffin, JD; Gu, H; Iwasaki, H; Li, S; Malouf, NA; Mohi, MG; Neel, BG; Podar, K; Pride, YB; Quinnan, LR; Sattler, M; Van Etten, RA1
Ball, G; Beran, M; Cortes-Franco, JE; Divoky, V; Gatto, S; Kantarjian, HM; Keating, MJ; Milella, M; Onida, F; Pham, L; Ricci, C; Scappini, B; Verstovsek, S1
Groffen, J; Heisterkamp, N; Zhang, B1
Roussel, MF; Sherr, CJ; Williams, RT1
Cunnick, JM; Groffen, J; Heisterkamp, N; Mishra, S; Zhang, B1
Majsterek, I; Pytel, D; Wysocki, T1
Butterfield, J; Kantarjian, H; Ketterling, R; Pardanani, A; Tefferi, A; Vaklavas, C; Verstovsek, S1
Baccarani, M; Martinelli, G; Paolini, S; Piccaluga, PP; Rondoni, M; Rosti, G1
Casadevall, N; Delmer, A; Legrand, O; Marie, JP; Rio, B; Ugo, V1

Reviews

2 review(s) available for imatinib mesylate and Leukemia, Lymphocytic

ArticleYear
Imatinib mesylate in the treatment of hematologic malignancies.
    Expert opinion on biological therapy, 2007, Volume: 7, Issue:10

    Topics: Animals; Antineoplastic Agents; Benzamides; Drug Interactions; Drug Resistance; Fusion Proteins, bcr-abl; Hematologic Neoplasms; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia, Lymphoid; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mastocytosis, Systemic; mRNA Cleavage and Polyadenylation Factors; Myeloproliferative Disorders; Oncogene Proteins, Fusion; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Treatment Outcome

2007
[Update on malignant hemopathies].
    Bulletin du cancer, 2002, Volume: 89, Issue:1

    Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Immunotoxins; Leukemia, Lymphoid; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Lymphoma; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Tretinoin

2002

Other Studies

8 other study(ies) available for imatinib mesylate and Leukemia, Lymphocytic

ArticleYear
Vincristine but not imatinib could suppress mesenchymal niche's support to lymphoid leukemic cells.
    Leukemia & lymphoma, 2010, Volume: 51, Issue:3

    Topics: Antineoplastic Agents; Asparaginase; Benzamides; Bone Marrow Cells; Coculture Techniques; Drug Screening Assays, Antitumor; Humans; Imatinib Mesylate; Inhibitory Concentration 50; Leukemia, Lymphoid; Mesenchymal Stem Cells; Mesoderm; Models, Biological; Piperazines; Pyrimidines; Stromal Cells; Tetrazolium Salts; Vincristine

2010
Critical role for Gab2 in transformation by BCR/ABL.
    Cancer cell, 2002, Volume: 1, Issue:5

    Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Benzamides; Cell Division; Cell Movement; Cell Transformation, Neoplastic; Erythroid Precursor Cells; Fusion Proteins, bcr-abl; GRB2 Adaptor Protein; Guanosine Triphosphate; Helminth Proteins; Humans; Imatinib Mesylate; Immunoblotting; Leukemia, Lymphoid; Mice; Mice, Knockout; Phosphatidylinositol 3-Kinases; Phosphorylation; Piperazines; Precipitin Tests; Proteins; Pyrimidines; Signal Transduction; Tyrosine

2002
The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate.
    Haematologica, 2003, Volume: 88, Issue:8

    Topics: Apoptosis; Benzamides; Boronic Acids; Bortezomib; Caspase 3; Caspases; Cell Cycle; Cell Line, Tumor; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; DNA-Binding Proteins; Drug Combinations; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Genes, abl; Humans; I-kappa B Proteins; Imatinib Mesylate; Leukemia, Lymphoid; Leukemia, Myeloid; Multienzyme Complexes; NF-kappa B; NF-KappaB Inhibitor alpha; Phosphorylation; Piperazines; Proteasome Endopeptidase Complex; Pyrazines; Pyrimidines

2003
Resistance to farnesyltransferase inhibitors in Bcr/Abl-positive lymphoblastic leukemia by increased expression of a novel ABC transporter homolog ATP11a.
    Blood, 2005, Aug-15, Volume: 106, Issue:4

    Topics: Alkyl and Aryl Transferases; Animals; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Benzamides; Coculture Techniques; Drug Resistance, Neoplasm; Enzyme Inhibitors; Farnesyltranstransferase; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Lymphoid; Mice; Piperazines; Pyrimidines; RNA, Small Interfering; Tumor Cells, Cultured; Vincristine

2005
Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia.
    Proceedings of the National Academy of Sciences of the United States of America, 2006, Apr-25, Volume: 103, Issue:17

    Topics: Alleles; Animals; Antineoplastic Agents; B-Lymphocytes; Benzamides; Bone Marrow Transplantation; Cyclin-Dependent Kinase Inhibitor p16; Genes, abl; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Interleukin-7; Leukemia, Lymphoid; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Neoplasm Transplantation; Piperazines; Pyrimidines; Tumor Cells, Cultured; Tumor Suppressor Protein p14ARF

2006
Resistance to imatinib of bcr/abl p190 lymphoblastic leukemia cells.
    Cancer research, 2006, May-15, Volume: 66, Issue:10

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Chemokine CXCL12; Chemokines, CXC; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Lymphoid; Mice; Mice, Nude; Piperazines; Point Mutation; Protein Structure, Tertiary; Pyrimidines; Stromal Cells

2006
Comparative study of DNA damage, cell cycle and apoptosis in human K562 and CCRF-CEM leukemia cells: role of BCR/ABL in therapeutic resistance.
    Comparative biochemistry and physiology. Toxicology & pharmacology : CBP, 2006, Volume: 144, Issue:1

    Topics: Antibiotics, Antineoplastic; Apoptosis; Benzamides; Caspase 3; Caspases; Cell Cycle; Cell Proliferation; DNA Damage; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Idarubicin; Imatinib Mesylate; K562 Cells; Leukemia, Lymphoid; Piperazines; Protein-Tyrosine Kinases; Pyrimidines

2006
'Idiopathic' eosinophilia with an Occult T-cell clone: prevalence and clinical course.
    Leukemia research, 2007, Volume: 31, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clone Cells; Cyclophosphamide; Eosinophilia; Female; Humans; Imatinib Mesylate; Leukemia, Lymphoid; Lymphoma, T-Cell, Peripheral; Male; Methotrexate; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Prevalence; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; T-Lymphocytes

2007